News & Events

New Receptor Protein-Tyrosine Kinases Study Findings Have Been Reported from Department of Medical Oncology (Heterogeneous efficacy and predictors of response to immunotherapy in driver-mutant advanced...

New Receptor Protein-Tyrosine Kinases Study Findings Have Been Reported from Department of Medical Oncology (Heterogeneous efficacy and predictors of response to immunotherapy in driver-mutant advanced...

2026 WCLC | GenFleet Therapeutics Announces Favorable Phase II Efficacy Data of GFH375 (Oral KRAS G12D Inhibitor) Monotherapy for Pretreated NSCLC in Oral Presentation at...

2026 WCLC | GenFleet Therapeutics Announces Favorable Phase II Efficacy Data of GFH375 (Oral KRAS G12D Inhibitor) Monotherapy for Pretreated NSCLC in Oral Presentation at...

Genfleet Therapeutics-B (02595): Superiority data from the Phase II monotherapy trial of GFH375 (an oral KRAS G12D inhibitor) for previously treated NSCLC presented as an oral report at the 2026 World Conference on Lung Cancer.

Genfleet Therapeutics-B (02595): Superiority data from the Phase II monotherapy trial of GFH375 (an oral KRAS G12D inhibitor) for previously treated NSCLC presented as an oral report at the 2026 World Conference on Lung Cancer.

Dr Veluswamy on the Emergence of KRAS G12C Inhibitors in NSCLC

Dr Veluswamy on the Emergence of KRAS G12C Inhibitors in NSCLC

Molecular concordance and clonal dynamics of KRAS mutations in lung adenocarcinoma across distinct clinical scenarios

Molecular concordance and clonal dynamics of KRAS mutations in lung adenocarcinoma across distinct clinical scenarios

Targetable KRAS G12C Mutation Uncommon in Genitourinary Cancers

Targetable KRAS G12C Mutation Uncommon in Genitourinary Cancers

BridgeBio Oncology reports new data for KRAS cancer drug BBO-8520

BridgeBio Oncology reports new data for KRAS cancer drug BBO-8520

New Xenografts Data Have Been Reported by Researchers at Jiangsu Province Academy of Traditional Chinese Medicine [Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib...

New Xenografts Data Have Been Reported by Researchers at Jiangsu Province Academy of Traditional Chinese Medicine [Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib...